journal cover

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood

Nov 13, 2019

Constantine S TamWilliam G Wierda

Get paper from

Abstract

Tam: Novartis: Honoraria; Pharmacyclics LLC, an AbbVie company: Honoraria; AbbVie: Honoraria, Research Funding; BeiGene: Honoraria; Janssen: Honoraria, Research Funding; Roche: Honoraria. Siddiqi:Astra Zeneca: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding, Speak...read more

Mentioned in this Paper

Pharmaceutical Preparations
Chronic Lymphocytic Leukemia
Research
Rocaltrol
Research Funding
Company (Organization)
Androderm
Thalomid
Drug Company
Tau-protein Kinase Activity
1
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood

Nov 13, 2019

Constantine S TamWilliam G Wierda

PMID: 31724017

DOI: 10.1182/blood-2019-121424

Abstract

Tam: Novartis: Honoraria; Pharmacyclics LLC, an AbbVie company: Honoraria; AbbVie: Honoraria, Research Funding; BeiGene: Honoraria; Janssen: Honoraria, Research Funding; Roche: Honoraria. Siddiqi:Astra Zeneca: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding, Speak...read more

Mentioned in this Paper

Pharmaceutical Preparations
Chronic Lymphocytic Leukemia
Research
Rocaltrol
Research Funding
1

Related Papers

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/ibrutinib-ibr-plus-venetoclax-ven-for-first-line/31724017